Dongqin Zhu
Research Subjects
Dongqin Zhu has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Hua Bao
Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, PR China
20 shared publications - Shanshan Yang
Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China
15 shared publications - Wanxiangfu Tang
Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China
15 shared publications - Xuxiaochen Wu
Nanjing Geneseeq Technology Inc., Nanjing 210061, China
15 shared publications - Chengshuai Si
Colorectal Center, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China. 1
13 shared publications - Dongsheng Yu
Colorectal Center, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China. 1
13 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S13 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This file contains supplementary figures illustrating the development and validation of the cfDNA-based pancreatic cancer detection model, including prediction score distributions across clinical subgroups, feature importance analyses, assessments of the limit of detection, and estimated screening benefits. It also includes representative medical imaging and pathological results of the pancreatic cancer related-cases identified in the prospective cohort.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S13 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This file contains supplementary figures illustrating the development and validation of the cfDNA-based pancreatic cancer detection model, including prediction score distributions across clinical subgroups, feature importance analyses, assessments of the limit of detection, and estimated screening benefits. It also includes representative medical imaging and pathological results of the pancreatic cancer related-cases identified in the prospective cohort.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S8 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This file includes supplementary tables summarizing cohort demographics, in silico and empirical estimates of the limit of detection (LOD), model performance across clinical and demographic subgroups, results from the non-pancreatic cancer disease cohort and prospective screening cohort, and simulated clinical impact in hypothetical populations.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S8 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This file includes supplementary tables summarizing cohort demographics, in silico and empirical estimates of the limit of detection (LOD), model performance across clinical and demographic subgroups, results from the non-pancreatic cancer disease cohort and prospective screening cohort, and simulated clinical impact in hypothetical populations.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
Pancreatic cancer remains a highly lethal malignancy due to late-stage diagnosis and limited therapeutic options. This study presents the development and validation of a noninvasive circulating cell-free DNA (cfDNA)–based model for early pancreatic cancer detection. In a case–control study comprising 232 patients with pancreatic cancer and 235 healthy controls, the model demonstrated high diagnostic accuracy (AUC = 0.9799 in training; 0.9622 in validation). A prospective cohort study involving 1,926 individuals with diabetes and obesity established risk factors for pancreatic cancer and further assessed its clinical applicability. The model detected 75% of pancreatic cancer cases, including all stage 0 patients, with a lead time of up to 298 days, significantly outperforming CA19-9. Additionally, it demonstrates potential for distinguishing high-risk from low-risk pancreatic cysts, thereby facilitating more precise risk stratification. This study highlights the potential of cfDNA-based screening as a scalable, noninvasive tool for early pancreatic cancer detection, warranting further large-scale clinical validation to enhance patient outcomes.Significance:This study develops a cfDNA-based model for early pancreatic cancer detection, demonstrating high accuracy and prospective clinical validation. By enabling presymptomatic identification and risk stratification, this noninvasive approach enhances early intervention and improves outcomes, supporting potential clinical applicability and representing a meaningful step toward improving pancreatic cancer screening and management.See related commentary by Tsui and Lo, p. 10
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
Pancreatic cancer remains a highly lethal malignancy due to late-stage diagnosis and limited therapeutic options. This study presents the development and validation of a noninvasive circulating cell-free DNA (cfDNA)–based model for early pancreatic cancer detection. In a case–control study comprising 232 patients with pancreatic cancer and 235 healthy controls, the model demonstrated high diagnostic accuracy (AUC = 0.9799 in training; 0.9622 in validation). A prospective cohort study involving 1,926 individuals with diabetes and obesity established risk factors for pancreatic cancer and further assessed its clinical applicability. The model detected 75% of pancreatic cancer cases, including all stage 0 patients, with a lead time of up to 298 days, significantly outperforming CA19-9. Additionally, it demonstrates potential for distinguishing high-risk from low-risk pancreatic cysts, thereby facilitating more precise risk stratification. This study highlights the potential of cfDNA-based screening as a scalable, noninvasive tool for early pancreatic cancer detection, warranting further large-scale clinical validation to enhance patient outcomes.Significance:This study develops a cfDNA-based model for early pancreatic cancer detection, demonstrating high accuracy and prospective clinical validation. By enabling presymptomatic identification and risk stratification, this noninvasive approach enhances early intervention and improves outcomes, supporting potential clinical applicability and representing a meaningful step toward improving pancreatic cancer screening and management.See related commentary by Tsui and Lo, p. 10
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Text 1 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This document provides detailed descriptions of patient recruitment procedures for the case-control cohort, methods for genomic feature extraction, model construction and training, statistical analyses, feature importance assessment, and both in silico and experimental evaluations of the limit of detection. It also includes the design of the prospective screening cohort and comprehensive clinical information on the pancreatic cancer–related cases identified therein.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Text 1 from Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer
This document provides detailed descriptions of patient recruitment procedures for the case-control cohort, methods for genomic feature extraction, model construction and training, statistical analyses, feature importance assessment, and both in silico and experimental evaluations of the limit of detection. It also includes the design of the prospective screening cohort and comprehensive clinical information on the pancreatic cancer–related cases identified therein.